CAPLYTA

all catalysts(0)

nothing on the calendar yet

News(2)

• As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the door
  Despite the recent emergence of a new drug class, schizophrenia remains one of the most challenging neuropsychiatric diseases to treat—and Cobenfy's first steps into the market indicate there is st…
  biospace · 8d ago
• J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals
  J&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s top venture rounds.
  biopharma_dive · 1mo ago